Evidence map›Paper›PMID 31059056›Full record

ArticleMolecular medicine reports2019

A five lncRNA signature for prognosis prediction in hepatocellular carcinoma.

Yongqiang Sun, Fangfang Zhang, Lifu Wang, Xueai Song, Jing Jing, Fan Zhang, Simiao Yu, Honghong Liu

Open access · bronzeAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yongqiang SunIntegrative Medical Center, 302 Military Hospital of China, Beijing 100039, P.R. China.
Fangfang ZhangOutpatient Department, 302 Military Hospital of China, Beijing 100039, P.R. China.
Lifu WangIntegrative Medical Center, 302 Military Hospital of China, Beijing 100039, P.R. China.
Xueai SongIntegrative Medical Center, 302 Military Hospital of China, Beijing 100039, P.R. China.
Jing JingIntegrative Medical Center, 302 Military Hospital of China, Beijing 100039, P.R. China.
Fan ZhangIntegrative Medical Center, 302 Military Hospital of China, Beijing 100039, P.R. China.
Simiao YuIntegrative Medical Center, 302 Military Hospital of China, Beijing 100039, P.R. China.
Honghong LiuInternational Center for Liver Disease Treatment, 302 Military Hospital of China, Beijing 100039, P.R. China.
302 Military Hospital of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was conducted to screen prognosis‑​associated long‑noncoding RNAs (lncRNAs) and a prognosis assessment model in hepatocellular carcinoma (HCC). lncRNA‑ and mRNA‑sequencing data of early‑stage HCC samples were downloaded from The Cancer Genome Atlas database. The samples were divided into training set and validation set. Differentially expressed lncRNAs (DELs) between poor prognosis and good prognosis samples were screened with DEseq and edgeR. Cox regression analysis was conducted to identify prognosis‑associated lncRNAs in the training set. A prognosis risk assessment model was established to calculate the risk score for each patient in the training set, and the prognosis prediction function was tested and validated in the validation dataset. The connection between the risk assessment model and clinical features was analyzed. A co‑expression network between lncRNAs and corresponding genes was constructed, and functional enrichment was performed for these genes. A total of 81 DELs were screened between poor and good prognosis samples in the training set, and 43 prognosis‑associated lncRNAs were observed. Of these DELs, five were used to construct the risk assessment model (RP11‑325L7.2, DKFZP434L187, RP11‑100L22.4, DLX2‑AS1 and RP11‑104L21.3). Low‑risk samples exhibited longer survival time compared with the high‑risk samples. The five lncRNAs exhibited significant differences in expression levels between different prognosis groups. Risk score was an independent prognostic factor for HCC. In the entire set, the low‑risk group demonstrated significantly better prognosis compared with the high‑risk group, even across all age, sex and alcohol consumption subgroups. 'Nucleoside‑triphosphatase regulator activity', 'GTPase regulator activity', 'enzyme binding', 'peroxisome proliferator‑activated receptor signaling pathway' and 'fatty acid metabolism' were the most significantly enriched functional terms. The signature lncRNAs screened in this study may have constitute novel strategies and biomarkers that predict the prognosis of HCC, and these may also contribute to a deeper understanding of the mechanisms underlying HCC development.

Indexed as

AgedArea Under CurveBiomarkers, TumorCarcinoma, HepatocellularDatabases, GeneticDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHepatitis, Viral, HumanHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID31059056
PMCPMC6522922
OpenAlexW2943456686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.